INTERVIEW: Pyott maps Botox and beyond path for 'growth junky' Allergan
This article was originally published in Scrip
Executive Summary
Allergan chairman, president and CEO David Pyott has set a goal of 10% revenue growth per year, but he isn't picky about where it comes from - therapeutics, aesthetics or medical devices - as long as the assets are differentiated from competing products in a way that they drive long-term revenue growth.
You may also be interested in...
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.
Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout
Dalzanemdor (SAGE-718) showed no difference from placebo in a Phase II Parkinson’s disease study, raising concerns about readouts later this year in Huntington’s and Alzheimer’s diseases.
First Phase III Depression Data For Intra-Cellular’s Caplyta Exceed Expectations
With positive results from the first Phase III trial of lumateperone in major depressive disorder and a second readout expected later this quarter, the company plans a supplemental filing in late 2024.